Voyager Therapeutics (NASDAQ:VYGR) Upgraded to “Buy” at StockNews.com

Voyager Therapeutics (NASDAQ:VYGR – Get Rating) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report released on Friday.

A number of other analysts have also issued reports on the stock. Chardan Capital lifted their price target on shares of Voyager Therapeutics from $4.00 to $6.00 in a research note on Wednesday, March 9th. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Saturday, March 12th. Finally, UBS Group decreased their price objective on shares of Voyager Therapeutics from $14.00 to $6.00 in a report on Monday, January 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $13.67.

NASDAQ VYGR traded up $0.23 during mid-day trading on Friday, hitting $7.48. The company’s stock had a trading volume of 1,009,311 shares, compared to its average volume of 751,159. The firm has a market capitalization of $285.10 million, a P/E ratio of -3.94 and a beta of 1.13. The stock’s fifty day simple moving average is $6.73 and its two-hundred day simple moving average is $4.46. Voyager Therapeutics has a 52-week low of $2.46 and a 52-week high of $10.60.

Voyager Therapeutics (NASDAQ:VYGR – Get Rating) last posted its quarterly earnings data on Tuesday, March 8th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.51. The company had revenue of $28.07 million for the quarter, compared to analyst estimates of $31.45 million. Voyager Therapeutics had a negative net margin of 190.30% and a negative return on equity of 66.35%. As a group, research analysts anticipate that Voyager Therapeutics will post -1.35 earnings per share for the current year.

In related news, VP Robert W. Hesslein sold 4,955 shares of Voyager Therapeutics stock in a transaction dated Monday, March 21st. The shares were sold at an average price of $8.29, for a total transaction of $41,076.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Robin Swartz sold 4,413 shares of Voyager Therapeutics stock in a transaction dated Monday, March 21st. The shares were sold at an average price of $8.29, for a total transaction of $36,583.77. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,933 shares of company stock valued at $124,170. Corporate insiders own 25.40% of the company’s stock.

A number of institutional investors have recently modified their holdings of VYGR. Royal Bank of Canada raised its holdings in Voyager Therapeutics by 160.7% during the 2nd quarter. Royal Bank of Canada now owns 5,937 shares of the company’s stock worth $25,000 after buying an additional 3,660 shares during the period. Bank of America Corp DE raised its holdings in Voyager Therapeutics by 34.3% during the 2nd quarter. Bank of America Corp DE now owns 29,896 shares of the company’s stock worth $124,000 after buying an additional 7,640 shares during the period. Wells Fargo & Company MN raised its holdings in Voyager Therapeutics by 27.9% during the 2nd quarter. Wells Fargo & Company MN now owns 100,243 shares of the company’s stock worth $414,000 after buying an additional 21,887 shares during the period. Morgan Stanley raised its holdings in Voyager Therapeutics by 58.6% during the 2nd quarter. Morgan Stanley now owns 734,609 shares of the company’s stock worth $3,035,000 after buying an additional 271,331 shares during the period. Finally, Parametric Portfolio Associates LLC purchased a new position in Voyager Therapeutics during the 2nd quarter valued at about $62,000. Hedge funds and other institutional investors own 63.55% of the company’s stock.

About Voyager Therapeutics (Get Rating)

Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.

See Also